 SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in November. 